Generic Valuation / Milestone QuestionTo those who are more pharma industry savvy, I know there is still a fair amount of uncertainty and risk and it's obviously reflected in the share price. But in a general sense, could something like a $2B valuation happen upon announcement of collaboration/investment (etc) with a big pharma co? Or would a valuation like that only occur after tangible commercialization type of activity is confirmed?
Maybe it's an even simpler equation, and AA (or regular approval) itself could be the catalyst for such a market valuation? I'm not sure of the milestone vs valuation dynamic. Sorry if it's an ignorant question.